

30 April 2024

**Privatisation by way of scheme of arrangement**

**Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited**

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

<b>Party</b>	<b>Date</b>	<b>Purchase / Sale</b>	<b>Number of shares</b>	<b>Price per share</b>	<b>Resultant balance (including those of any person with whom there is an agreement or understanding)</b>	<b>Percentage of class (including those of any person with whom there is an agreement or understanding)</b>
Pan Rongrong	29 April 2024	Purchase	57,500	\$0.0000	160,667	0.0256%

End

Note:

Pan Rongrong is a Class (1) associate connected with the Offeree company by virtue of class (2) of the definition of acting in concert and a party acting in concert with the Offeror.

Dealings were made for her own account.

On 29 April 2024, 57,500 share awards were vested on Pan Rongrong pursuant to the Post-IPO RSU Plan adopted by the Company.